🎯 check Zoldonrasib (RMC-9805) product page
RMC-9805 is an orally bioavailable, and mutant-selective covalent KRAS G12D (ON) inhibitor. It works by selectively binding to and inhibiting mutant KRAS G12D in its active, GTP-bound state, disrupting downstream oncogenic Ras signaling pathways. This pharmacological intervention effectively induces apoptosis and drives robust tumor regression in preclinical models of KRAS G12D-mutated malignancies.